About Us
Refuge is a cancer immunotherapy company leveraging synthetic biology and gene engineering to unlock the full promise of cell therapies. We create cell therapies that sense their surroundings and conditionally activate or repress multiple genes simultaneously – resulting in more potent and targeted treatments beyond a single target and function.
Scientific Illustrations
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
1
scFV Receptor
2
Spacer
3
Cell Membrane
4
CD-28/4-1BB
5
CD-3ζ
6
Protease
7
Adaptor
8
Cleavable Linker
9
dCAS9
10
KRAB
11
Nuclear Membrane
12
TIM-3 gRNA
13
PD-1 gRNA
14
TIM-3
15
PD-1
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
1
scFV Receptor
2
Spacer
3
Cell Membrane
4
CD-28/4-1BB
5
CD-3ζ
6
Protease
7
Adaptor
8
Cleavable Linker
9
dCAS9
10
KRAB
11
Nuclear Membrane
12
TIM-3 gRNA
13
PD-1 gRNA
14
TIM-3
15
PD-1
16
Tumor Antigen
1
2
3
4
5
6
7
8
9
10
11
12
13
14
1
scFV Receptor
2
Spacer
3
Cell Membrane
4
CD-28/4-1BB
5
CD-3ζ
6
Protease
7
Adaptor
8
Cleavable Linker
9
Nuclear Membrane
10
TIM-3 gRNA
11
PD-1 gRNA
12
TIM-3
13
PD-1
14
Tumor Antigen
1
2
3
4
5
6
7
8
9
10
11
12
13
1
scFV Receptor
2
Spacer
3
Cell Membrane
4
CD-28/4-1BB
5
CD-3ζ
6
Protease
7
Adaptor
8
Nuclear Membrane
9
TIM-3 gRNA
10
PD-1 gRNA
11
TIM-3
12
PD-1
13
Tumor Antigen
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
1
scFV Receptor
2
Spacer
3
Cell Membrane
4
CD-28/4-1BB
5
CD-3ζ
6
Protease
7
Adaptor
8
Cleavable Linker
9
dCAS9
10
KRAB
11
Nuclear Membrane
12
TIM-3 gRNA
13
PD-1 gRNA
14
TIM-3
15
PD-1
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
1
scFV Receptor
2
Spacer
3
Cell Membrane
4
CD-28/4-1BB
5
CD-3ζ
6
Protease
7
Adaptor
8
Cleavable Linker
9
dCAS9
10
KRAB
11
Nuclear Membrane
12
TIM-3 gRNA
13
PD-1 gRNA
14
TIM-3
15
PD-1
16
Tumor Antigen
1
2
3
4
5
6
7
8
9
10
11
12
13
1
scFV Receptor
2
Spacer
3
Cell Membrane
4
CD-28/4-1BB
5
CD-3ζ
6
Protease
7
Adaptor
8
Nuclear Membrane
9
TIM-3 gRNA
10
PD-1 gRNA
11
TIM-3
12
PD-1
13
Tumor Antigen
1
2
3
4
5
6
7
8
9
10
11
12
13
1
scFV Receptor
2
Spacer
3
Cell Membrane
4
CD-28/4-1BB
5
CD-3ζ
6
Protease
7
Adaptor
8
Nuclear Membrane
9
TIM-3 gRNA
10
PD-1 gRNA
11
TIM-3
12
PD-1
13
Tumor Antigen
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
1
scFV Receptor
2
Spacer
3
Cell Membrane
4
CD-28/4-1BB
5
CD-3ζ
6
Protease
7
Adaptor
8
Cleavable Linker
9
dCAS9
10
KRAB
11
Nuclear Membrane
12
TIM-3 gRNA
13
PD-1 gRNA
14
TIM-3
15
PD-1
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
1
Tumor Antigen
2
scFV Receptor
3
Spacer
4
Cell Membrane
5
CD-28/4-1BB
6
CD-3ζ
7
Protease
8
Adaptor
9
Cleavable Linker
10
dCAS9
11
KRAB
12
Nuclear Membrane
13
TIM-3 gRNA
14
PD-1 gRNA
15
TIM-3
16
PD-1
1
2
3
4
5
6
7
8
9
10
11
12
13
14
1
Tumor Antigen
2
scFV Receptor
3
Spacer
4
Cell Membrane
5
CD-28/4-1BB
6
CD-3ζ
7
Protease
8
Adaptor
9
Cleavable Linker
10
Nuclear Membrane
11
TIM-3 gRNA
12
PD-1 gRNA
13
TIM-3
14
PD-1
1
2
3
4
5
6
7
8
9
10
11
12
13
1
Tumor Antigen
2
scFV Receptor
3
Spacer
4
Cell Membrane
5
CD-28/4-1BB
6
CD-3ζ
7
Protease
8
Adaptor
9
Nuclear Membrane
10
TIM-3 gRNA
11
PD-1 gRNA
12
TIM-3
13
PD-1
Programs
Management Team
Board of Directors
Scientific Founders
Media
Professor Stanley Qi gave a talk on gene editing and gene expression control at the 2016 Tencent WE conference in Beijing. (In Chinese)
Dr. Bing Wang gave a talk on Refuge Biotechnologies’ therapeutic platform at the 2017 Pioneers Festival in Vienna.
An Effort to Develop Safer and More Effective Immunotherapies by The Bio Report